NFE2L1 and cancer: The interaction between PD‐1 on T cells and PD‐L1 on tumor cells impedes the cancer immunity cycle [60], suggesting a model where inhibition of NFE2L1 leads to immune activation and a shift of the TME toward a more inflammatory state.